High Speed Roll Printing Syringe Machine

Shisiyao achieved medical needle loader revenue of HK$4. The industry believes that in the medium and long term, in the context of the promotion of consistency evaluation and the intensified aging trend, innovative drugs and generic drugs still have greater opportunities. The industry expects that the company's many drugs under research can become new growth engines, and the major shareholder-controlled Dongyang Sunshine Research Institute is expected to continue to inject innovative drug products into it in the future. Among them, Shisiyao's intravenous infusion products continued to perform strongly in 2018, with a revenue of 3. As of July this year, Hansen Pharma has 13 main products, including 11 first generic drugs such as Class 1.6%; net profit was 952 million yuan, a year-on-year increase of 28. This year's large infusion sales target exceeds 1.181 billion in 2018, a year-on-year increase of 35. From 2018 to July this year, a total of 20 generic drugs have been approved.　　 In addition, the reform of the domestic generic drug market is also expected to bring new opportunities to the company.8% of the company's revenue; Enbipu increased by 32. The diversified drug portfolio is expected to enhance its sales capabilities in multiple therapeutic areas..9%; net profit increased for three consecutive times, reaching HK$912 million in 2018, a year-on-year increase of 37. Among them, Sino Biopharmaceuticals As more varieties pass the consistency evaluation, the clinical substitution of the original research drug can be further realized, and more advantages can be obtained at the level of market expansion and medical insurance payment.[Pharmaceutical Network Industry News] With the implementation of '4+7' mass procurement, the pharmaceutical landscape is facing changes and market competition is becoming more intense.　　Dongyang Pharmaceutical: A diversified drug portfolio　　　　　　Dongyang Pharmaceutical is active in generic drugs and innov,medical needle loader ...ادامه مطلب